

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method for the treatment of cancerous cell growth mediated by raf kinase comprising administering a compound of formula I



wherein B is phenyl substituted by ~~-Y-Ar~~, ~~pyridinyl~~, ~~pyrimidinyl~~, ~~pyrazinyl~~, ~~pyridazinyl~~, ~~naphthyl~~, ~~quinolinyl~~, ~~isoquinolinyl~~, ~~phthalimidinyl~~, ~~furyl~~, ~~thienyl~~, ~~pyrrolyl~~, ~~imidazolyl~~, ~~pyrazolyl~~, ~~oxazolyl~~, ~~isoxazolyl~~, ~~thiazolyl~~, ~~isothiazolyl~~, ~~benzofuryl~~, ~~benzothienyl~~, ~~indolyl~~, ~~benzopyrazolyl~~, ~~benzoxazolyl~~, ~~benzisoxazolyl~~, ~~benzothiazolyl~~ or ~~benzisoethiazolyl~~, and optionally substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and X_n , wherein n is 0-3 and each X is independently selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{NO}_2$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_2\text{-C}_{10}$ alkenyl, $\text{C}_1\text{-C}_{10}$ alkoxy, $\text{C}_3\text{-C}_{10}$ cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl, quinolinyl up to per halo-substituted $\text{C}_1\text{-C}_{10}$ alkyl, up to per halo-substituted $\text{C}_2\text{-C}_{10}$ alkenyl, up to per halo-substituted $\text{C}_1\text{-C}_{10}$ alkoxy, up to per halo-substituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, and ~~-Y-Ar~~;

wherein R^5 and R^5 are independently selected from H, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_2\text{-C}_{10}$ alkenyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, up to per-halosubstituted $\text{C}_1\text{-C}_{10}$ alkyl, up to per-halosubstituted $\text{C}_2\text{-C}_{10}$ alkenyl and up to per-halosubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl,

wherein Y is ~~-O-~~, ~~or -S-~~, ~~$\text{N}(\text{R}^5)$~~ , ~~$(\text{CH}_2)_m\text{-C}(\text{O})$~~ , ~~$\text{CH}(\text{OH})$~~ , ~~$(\text{CH}_2)_m\text{O}$~~ , ~~$\text{NR}^5\text{C}(\text{O})\text{NR}^5\text{NR}^5$~~ , ~~$\text{NR}^5\text{C}(\text{O})$~~ , ~~$\text{C}(\text{O})\text{NR}^5$~~ , ~~$(\text{CH}_2)_m\text{S}$~~ , ~~$(\text{CH}_2)_m\text{N}(\text{R}^5)$~~ , ~~$\text{O}(\text{CH}_2)_m$~~ , ~~$\text{CHX}^a$~~ , ~~$\text{CX}^a_2$~~ , ~~$\text{S}(\text{CH}_2)_m$~~ and ~~$\text{N}(\text{R}^5)(\text{CH}_2)_m$~~ ,


~~$m=1-3$~~ , and ~~X^a is halogen~~; and

Ar is phenyl, ~~or pyridinyl~~, ~~pyrimidinyl~~, ~~pyrazinyl~~, ~~pyridazinyl~~, ~~naphthyl~~, ~~quinolinyl~~, ~~isoquinolinyl~~, ~~phthalimidinyl~~, ~~furyl~~, ~~thienyl~~, ~~pyrrolyl~~, ~~imidazolyl~~, ~~pyrazolyl~~, ~~oxazolyl~~, ~~isoxazolyl~~, ~~thiazolyl~~, ~~isothiazolyl~~, ~~benzofuryl~~, ~~benzothienyl~~, ~~indolyl~~, ~~benzopyrazolyl~~, ~~benzoxazolyl~~, ~~benzisoxazolyl~~, ~~benzothiazolyl~~ or ~~benzisoethiazolyl~~, optionally substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1} , wherein $n1$ is 0 to 3 and

each Z is independently selected from the group consisting of $-\text{CN}$, $=\text{O}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{C}(\text{O})-\text{NR}^5$, $-\text{NO}_2$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, $-\text{SO}_2\text{R}^5$, $\text{SO}_2\text{NR}^5\text{R}^5$, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_1\text{-C}_{10}$ alkoxy, $\text{C}_3\text{-C}_{10}$ cycloalkyl, up to per halo-substituted $\text{C}_1\text{-C}_{10}$ alkyl, and up to per halo-substituted $\text{C}_3\text{-C}_{10}$ cycloalkyl,

and

A is a heteroaryl moiety selected from the group consisting of



wherein

R^1 is selected from the group consisting of halogen, $\text{C}_3\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_1\text{-C}_{13}$ heteroaryl, $\text{C}_6\text{-C}_{14}$ aryl, $\text{C}_7\text{-C}_{24}$ alkaryl, up to per-halosubstituted $\text{C}_1\text{-C}_{10}$ alkyl, up to per-halosubstituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, up to per-halosubstituted $\text{C}_1\text{-C}_{13}$ heteroaryl, up to per-halosubstituted $\text{C}_6\text{-C}_{14}$ aryl, and up to per-halosubstituted $\text{C}_7\text{-C}_{24}$ alkaryl;

~~R^2 is selected from the group consisting of H , $\text{C}(\text{O})\text{R}^4$, CO_2R^4 , $\text{C}(\text{O})\text{NR}^3\text{R}^3$, $\text{C}_1\text{-C}_{10}$ alkyl, $\text{C}_3\text{-C}_{10}$ cycloalkyl, $\text{C}_7\text{-C}_{24}$ alkaryl, $\text{C}_4\text{-C}_{23}$ alkheteroaryl, substituted $\text{C}_1\text{-C}_{10}$ alkyl, substituted $\text{C}_3\text{-C}_{10}$ cycloalkyl, substituted $\text{C}_7\text{-C}_{24}$ alkaryl and substituted $\text{C}_4\text{-C}_{23}$ alkheteroaryl;~~

~~where R^2 is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of CN , CO_2R^4 , $\text{C}(\text{O})\text{NR}^3\text{R}^3$, NO_2 , OR^4 , SR^4 , and halogen up to per halosubstitution;~~


wherein R^3 and R^2 are independently selected from the group consisting of H, OR^4 , SR^4 , NR^4R^4 , $C(O)R^4$, CO_2R^4 , $C(O)NR^4R^4$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl or quinolinyl up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, and up to per-halosubstituted, phenyl, pyridinyl, naphthyl, isoquinolinyl or quinolinyl; and

wherein R^4 and R^4 are independently selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl, quinolinyl up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, and up to per-halosubstituted, phenyl, pyridinyl, naphthyl, isoquinolinyl or quinolinyl


R^a is C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl and up to per-halosubstituted C_3-C_{10} cycloalkyl; and

R^b is hydrogen or halogen;

R^c is hydrogen, halogen, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl or combines with R^1 and the ring carbon atoms to which R^1 and R^c are bound to form a 5- or 6-membered cycloalkyl, aryl or hetaryl ring with 0-2 members selected from O, N and S; subject to the proviso that where A is




B is not




wherein $n = 2-4$,

or



2-8. (Cancelled)

9. (Original) A method as in claim 1 comprising administering a compound



of the formula

wherein R¹ and B are as defined in claim 1.


10. (Cancelled)

11. (Currently Amended) A method as in claim 1 comprising administering a compound selected from the group consisting of:

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-benzoylphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;
~~*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;~~
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea; and
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea; and
~~*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea~~
 and pharmaceutically acceptable salts thereof.

12. (Previously Presented) A method as in claim 9, wherein R¹ is t-butyl.

13. (Original) A method as in claim 1 comprising administering a compound of the formula



wherein R¹ and B are as defined in claim 1.

14. (Cancelled)

15. (Currently Amended) A method as in claim 1 comprising administering a compound selected from the group consisting of

N-(3-Isopropyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;

~~*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(5-(2-(4-acetylphenyl)oxy)pyridinyl)urea;~~

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

~~*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;~~

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methyl-3-pyridinyl)oxyphenyl)urea;

~~*N*-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;~~

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-methylphenyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

~~*N*-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(5-(2-(4-methoxyphenyl)oxy)pyridinyl)urea;~~

N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea; and


N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

and pharmaceutically acceptable salts thereof.

16. (Original) A method as in claim 13, wherein R^1 is t-butyl.

17-36. (Cancelled)

37. (Withdrawn and Currently Amended) A compound of the formula



wherein R^1 is selected from the group consisting of C_3 - C_6 alkyl, C_3 - C_{10} cycloalkyl, up to per-halosubstituted C_3 - C_6 alkyl and up to per-halosubstituted C_3 - C_{10} cycloalkyl;

B is phenyl substituted by X, pyridinyl, indolinyl, isoquinolinyl, quinolinyl or naphthyl which is substituted by X, and optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by X^n wherein $n = 0-2$;

each X^1 is independently selected from the group of X or from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{OR}^5$, $-\text{NO}_2$, $-\text{NR}^5\text{R}^5$, C_1 - C_{10} alkyl, C_{2-10} -alkenyl, C_{1-10} -alkoxy, C_3 - C_{10} cycloalkyl, and C_6 - C_{14} and

X is selected from the group consisting of $-\text{SR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, C_3 - C_{13} heteroaryl, substituted C_4 - C_{10} alkyl, substituted C_{2-10} alkenyl, substituted C_{1-10} alkoxy, substituted C_3 - C_{10} cycloalkyl, substituted C_6 - C_{14} aryl, substituted C_3 - C_{13} heteroaryl, and $-\text{Y}-\text{Ar}$, and

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^5$, NO_2 , $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$ and halogen up to per-halosubstitution;


wherein R^5 and R^5 are independently selected from H, C_1 - C_{10} alkyl, C_{2-10} -alkenyl, C_3 - C_{10} cycloalkyl, C_6 - C_{14} aryl, C_3 - C_{13} heteroaryl, C_7 - C_{24} alkaryl, C_4 - C_{23} alkheteroaryl, up to per-halosubstituted C_1 - C_{10} alkyl, up to per-halosubstituted C_{2-10} -alkenyl, and up to per-halosubstituted C_3 - C_{10} cycloalkyl, wherein

Y is - O-, or -S-, ~~N(R⁵), (CH₂)_m, C(O), CH(OH), (CH₂)_mO, NR⁵C(O)NR⁵R⁵-,~~
~~NR⁵C(O), C(O)NR⁵, (CH₂)_mS, (CH₂)_mN(R⁵), O(CH₂)_m, CHX^a, CX^a₂, S(CH₂)_m-~~
 and ~~N(R⁵)(CH₂)_m-~~


~~m = 1-3, and X^a is halogen; and~~

Ar is wherein B is phenyl, or pyridinyl, ~~pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl,~~
~~quinolinyl, isoquinolinyl, phthalimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl,~~
~~oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzofuryl, benzothienyl, indolyl,~~
~~benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or benzisothiazolyl,~~ which is
 unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{nl},
 wherein nl is 0 to 3 and each Z is independently selected from the group consisting of -CN, -
 CO₂R⁵, -C(O)R⁵, =O, -C(O)NR⁵R⁵, -C(O)R⁵, -NO₂, -OR⁵, -SR⁵, -NR⁵R⁵, -NR⁵C(O)OR⁵, -
 NR⁵C(O)R⁵, -SO₂R⁵, -SO₂R⁵R⁵, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkyl, substituted
 C₁-C₁₀ alkyl, and substituted C₃-C₁₀ cycloalkyl, wherein if Z is a substituted group, it is
 substituted by one or more substituents independently selected from the group consisting of -
 CN, -CO₂R⁵, -C(O)NR⁵R⁵, =O, -OR⁵, -SR⁵, -NO₂, -NR⁵R⁵, -NR⁵C(O)R⁵, -NR⁵C(O)OR⁵,
 C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, and C₃-C₁₀ cycloalkyl,

subject to the proviso that where R¹ is t-butyl, B is not



wherein R⁶ is -NHC(O)-O-t-butyl, -O-n-pentyl, -O-n-butyl, -O-n-propyl,
 -C(O)NH-(CH₃)₂, -OCH₂CH(CH₃)₂, or




38-40. (Cancelled)

41. (Withdrawn and Currently Amended) A compound as in claim 37
 selected from the group consisting of:

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;
~~*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-benzoylphenyl)urea;~~
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;
~~*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;~~
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea;
~~*N*-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;~~
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(2-methyl-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea; and
N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(3-methylcarbamoyl)phenyl)oxyphenyl) urea;
 and pharmaceutically acceptable salts thereof.



wherein B is as defined in claim 37 5-methyl-2-thienyl or selected from the group consisting of phenyl, or pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzofuryl, benzothienyl, indolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or benzisothiazolyl, substituted one or more substituents independently selected from the group consisting of halogen, up to per halosubstitution, and X_n ;

wherein n is 0-3 and each X is independently selected from the group consisting of CN , CO_2R^5 , $C(O)NR^5R^5$, $C(O)R^5$, NO_2 , OR^5 , SR^5 , NR^5R^5 , $NR^5C(O)OR^5$, $NR^5C(O)R^5$, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_1 - C_{10} alkoxy, C_3 - C_{10} cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl, quinolinyl, up to per halo-substituted C_1 - C_{10} alkyl, up to per halo-substituted C_2 - C_{10} alkenyl, up to per halo-substituted C_1 - C_{10} alkoxy and, up to per halo-substituted C_3 - C_{10} cycloalkyl;

wherein R^5 and R^5 are independently selected from H, C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_3 - C_{10} cycloalkyl, phenyl, pyridinyl, naphthyl, isoquinolinyl, quinolinyl up to per halosubstituted C_1 - C_{10} alkyl, up to per halosubstituted C_2 - C_{10} alkenyl, and up to per halosubstituted C_3 - C_{10} cycloalkyl;

wherein Y is O, or S, $N(R^5)$, $(CH_2)_m$, $C(O)$, $CH(OH)$, $(CH_2)_mO$, $NR^5C(O)NR^5NR^5$, $NR^5C(O)$, $C(O)NR^5$, $(CH_2)_mS$, $(CH_2)_mN(R^5)$, $O(CH_2)_m$, CHX^a , CX^a_2 , $S(CH_2)_m$ and $N(R^5)(CH_2)_m$;


$m = 1-3$, and X^a is halogen; and

Ar is phenyl, or pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzofuryl, benzothienyl, indolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or benzisothiazolyl, optionally substituted by


halogen up to per-halosubstitution and optionally substituted by Z_{n1} ;

— wherein $n1$ is 0 to 3 and each Z is independently selected from the group consisting of $-\text{CN}$, $-\text{O}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5$, $-\text{NO}_2$, $-\text{OR}^5$, $-\text{SR}^5$, $-\text{NR}^5\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$, $-\text{SO}_2\text{R}^5$, $-\text{SO}_2\text{NR}^5\text{R}^5$, C_1 - C_{10} -alkyl, C_1 - C_{10} -alkoxyl, C_3 - C_{10} -cycloalkyl, up to per-halo-substituted C_1 - C_{10} -alkyl and up to per-halo-substituted C_3 - C_{10} -cycloalkyl; subject to the proviso that


~~B is not~~



wherein R^6 is ~~$\text{NHC}(\text{O})\text{O}$ t butyl, O n pentyl, O n butyl, O n propyl, $-\text{C}(\text{O})\text{NH}(\text{CH}_3)_2$, $-\text{OCH}_2\text{CH}(\text{CH}_3)_2$, or~~



43. (Currently Amended) A compound of the formula



wherein R^1 is selected from the group consisting of C_3 - C_6 alkyl, C_3 - C_6 cycloalkyl, up to per-halosubstituted C_3 - C_6 alkyl, and up to per-halosubstituted C_3 - C_6 cycloalkyl, and

B is phenyl, ~~pyridinyl, indolinyl, isoquinolinyl, quinolinyl or naphthyl~~, which is substituted by X , and optionally substituted by halogen, up to per-halosubstitution, and optionally substituted by X^1_n , wherein $n = 0-2$;

each X^1 is independently selected from the group of X or from the group consisting of $-\text{CN}$, $-\text{CO}_2\text{R}^5$, $-\text{C}(\text{O})\text{R}^5$, $-\text{C}(\text{O})\text{NR}^5\text{R}^5$, $-\text{OR}^5$, $-\text{NO}_2$, $-\text{NR}^5\text{R}^5$, C_1 - C_{10} alkyl, C_2 - C_{10} -alkenyl, C_1 - C_{10} -alkoxy, C_3 - C_{10} cycloalkyl, C_6 - C_{14} aryl and C_7 - C_{24} alkaryl, and

X is $-\text{Y}-\text{Ar}$, ~~selected from the group consisting of $-\text{SR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{OR}^5$, $-\text{NR}^5\text{C}(\text{O})\text{R}^5$,~~

~~C₃-C₁₃ heteroaryl, substituted C₁-C₁₀ alkyl, substituted C₂₋₁₀ alkenyl, substituted C₁₋₁₀ alkoxy, substituted C₃-C₁₀ cycloalkyl, substituted C₆-C₁₄ aryl, substituted C₃-C₁₃ heteroaryl, and Y~~
~~Ar~~, and wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, CO₂R^S, -C(O)R^S, -C(O)NR^SR^{S'}, -OR^S, -SR^S, -NR^SR^{S'}, NO₂, -NR^SC(O)R^S, -NR^SC(O)OR^S and halogen up to per-halosubstitution;


wherein R^S and R^{S'} are independently selected from H, C₁-C₁₀ alkyl, C₂₋₁₀-alkenyl, C₃-C₁₀ cycloalkyl, C₆-C₁₄ aryl, C₃-C₁₃ heteroaryl, C₇-C₂₄ alkaryl, C₄-C₂₃ alkheteroaryl, up to per-halosubstituted C₁-C₁₀ alkyl, up to per-halosubstituted C₂₋₁₀-alkenyl, and up to per-halosubstituted C₃-C₁₀ cycloalkyl, wherein

Y is -O-, ~~or -S-, -N(R^S)-, (CH₂)_m-, C(O)-, CH(OH)-, (CH₂)_mO-, NR^SC(O)NR^SR^{S'}-, NR^SC(O)-, C(O)NR^S-, (CH₂)_mS-, (CH₂)_mN(R^S)-, O(CH₂)_m-, CHX^a-, CX^a₂-, S(CH₂)_m- and N(R^S)(CH₂)_m-,~~

~~m = 1-3, and X^a is halogen; and~~

Ar is phenyl, ~~or pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, naphthyl, quinolinyl, isoquinolinyl, phthalimidinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, benzofuryl, benzothienyl, indolyl, benzopyrazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl or benzisothiazolyl,~~ which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of -CN, -CO₂R^S, -C(O)R^S, =O, -C(O)NR^SR^{S'}, -C(O)R^S, -NO₂, -OR^S, -SR^S, -NR^SR^{S'}, -NR^SC(O)OR^S, -NR^SC(O)R^S, -SO₂R^S, -SO₂R^SR^{S'}, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, C₃-C₁₀ cycloalkyl, substituted C₁-C₁₀ alkyl, and substituted C₃-C₁₀ cycloalkyl, wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, -CO₂R^S, -C(O)NR^SR^{S'}, =O, -OR^S, -SR^S, -NO₂, -NR^SR^{S'}, -NR^SC(O)R^S and -NR^SC(O)OR^S, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, and C₃-C₁₀ cycloalkyl,
 and where R¹ is -CH₂-t-butyl,


B is not



44-45. (Cancelled)

46. (Withdrawn and Currently Amended)

A compound of the formula



wherein B is as defined in claim 43 +.

47-79. (Cancel)

80. (New) A method according to claim 1, wherein the cancerous cell growth is mediated by raf kinase.